INS and type 1 diabetes mellitus: This explains why such therapies for patients with T1DM, e.g. with an anti-CD3 monotherapy [34–40], through insulin immunisation [12, 41, 42] or other autoantigen treatments [12, 41], have been unsuccessful in reversing the diabetic metabolic state in patients with stage 3 of T1DM.